Insmed, Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 8 of 8 compared factors.
Size & Scale
| INSM | LLY | |
|---|---|---|
| Market Cap | $28.26 billion | $1.05 trillion |
| Revenue (TTM) | $1.14 billion | $79.67 billion |
| Net Income (TTM) | $-875,311,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| INSM | LLY | |
|---|---|---|
| P/E Ratio | — | 39.73 |
| Price / Book | 37.31 | 31.14 |
| Price / Sales | 24.84 | 13.24 |
LLY leads on 2 of 2 valuation factors.
Profitability
| INSM | LLY | |
|---|---|---|
| Net Margin | -76.94% | 33.53% |
| Return on Equity | -115.55% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| INSM | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
INSM and LLY split the dividend factors evenly.
Risk & Sentiment
| INSM | LLY | |
|---|---|---|
| Short Interest | 2.48% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: INSM overview, INSM financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.